Cargando…

Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience

SIMPLE SUMMARY: Conversion surgery has been increasingly performed for initially unresectable advanced pancreatic ductal adenocarcinoma (PDAC). Patients with PDAC were classified into three groups: resectable (R), borderline resectable (BR), and unresectable (UR). In total, 211 patients (R, 118; BR,...

Descripción completa

Detalles Bibliográficos
Autores principales: Einama, Takahiro, Takihata, Yasuhiro, Aosasa, Suefumi, Konno, Fukumi, Kobayashi, Kazuki, Yonamine, Naoto, Fujinuma, Ibuki, Tsunenari, Takazumi, Nakazawa, Akiko, Shinto, Eiji, Ueno, Hideki, Kishi, Yoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954753/
https://www.ncbi.nlm.nih.gov/pubmed/36831444
http://dx.doi.org/10.3390/cancers15041101
_version_ 1784894194426314752
author Einama, Takahiro
Takihata, Yasuhiro
Aosasa, Suefumi
Konno, Fukumi
Kobayashi, Kazuki
Yonamine, Naoto
Fujinuma, Ibuki
Tsunenari, Takazumi
Nakazawa, Akiko
Shinto, Eiji
Ueno, Hideki
Kishi, Yoji
author_facet Einama, Takahiro
Takihata, Yasuhiro
Aosasa, Suefumi
Konno, Fukumi
Kobayashi, Kazuki
Yonamine, Naoto
Fujinuma, Ibuki
Tsunenari, Takazumi
Nakazawa, Akiko
Shinto, Eiji
Ueno, Hideki
Kishi, Yoji
author_sort Einama, Takahiro
collection PubMed
description SIMPLE SUMMARY: Conversion surgery has been increasingly performed for initially unresectable advanced pancreatic ductal adenocarcinoma (PDAC). Patients with PDAC were classified into three groups: resectable (R), borderline resectable (BR), and unresectable (UR). In total, 211 patients (R, 118; BR, 22; UR, 81) were selected. Among them, 117 (99%), 18 (82%), and 15 (19%) patients in the R, BR, and UR groups underwent surgical resection. R0 resection rates were 88%, 78%, and 67%, whereas median overall survival (OS) rates from treatment initiation were 31, 18, and 11 months (p < 0.0001) in the R, BR, and UR groups, respectively. In patients who underwent surgical resection, relapse-free survival (RFS) and OS were similar. Lymph node metastases and incomplete adjuvant chemotherapy were identified as independent prognostic factors for OS. ABSTRACT: Although conversion surgery has increasingly been performed for initially unresectable advanced pancreatic ductal adenocarcinoma (PDAC), the rate of conversion, including that for patients who do not undergo resection, remains unclear. Patients with PDAC who were treated between January 2013 and December 2018 were classified into three groups: resectable (R), borderline resectable (BR), and unresectable (UR). We analyzed patient outcomes, including the rate of surgical resection and survival, in each of these groups. In total, 211 patients (R, 118; BR, 22; UR, 81) were selected. Among them, 117 (99%), 18 (82%), and 15 (19%) patients in the R, BR, and UR groups, respectively, underwent surgical resection. R0 resection rates were 88, 78, and 67%, whereas median overall survival (OS) from treatment initiation were 31, 18, and 11 months (p < 0.0001) in the R, BR, and UR groups, respectively. In patients who underwent surgical resection, relapse-free survival (RFS) and OS were similar among the three groups (R vs. BR vs. UR; median RFS (months), 17 vs. 13 vs. 11, p = 0.249; median OS (months), 31 vs. 26 vs. 32, p = 0.742). Lymph node metastases and incomplete adjuvant chemotherapy were identified as independent prognostic factors for OS. Although the surgical resection rate was low, particularly in the BR and UR groups, the prognosis of patients who underwent surgical resection was similar irrespective of the initial resectability status.
format Online
Article
Text
id pubmed-9954753
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99547532023-02-25 Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience Einama, Takahiro Takihata, Yasuhiro Aosasa, Suefumi Konno, Fukumi Kobayashi, Kazuki Yonamine, Naoto Fujinuma, Ibuki Tsunenari, Takazumi Nakazawa, Akiko Shinto, Eiji Ueno, Hideki Kishi, Yoji Cancers (Basel) Article SIMPLE SUMMARY: Conversion surgery has been increasingly performed for initially unresectable advanced pancreatic ductal adenocarcinoma (PDAC). Patients with PDAC were classified into three groups: resectable (R), borderline resectable (BR), and unresectable (UR). In total, 211 patients (R, 118; BR, 22; UR, 81) were selected. Among them, 117 (99%), 18 (82%), and 15 (19%) patients in the R, BR, and UR groups underwent surgical resection. R0 resection rates were 88%, 78%, and 67%, whereas median overall survival (OS) rates from treatment initiation were 31, 18, and 11 months (p < 0.0001) in the R, BR, and UR groups, respectively. In patients who underwent surgical resection, relapse-free survival (RFS) and OS were similar. Lymph node metastases and incomplete adjuvant chemotherapy were identified as independent prognostic factors for OS. ABSTRACT: Although conversion surgery has increasingly been performed for initially unresectable advanced pancreatic ductal adenocarcinoma (PDAC), the rate of conversion, including that for patients who do not undergo resection, remains unclear. Patients with PDAC who were treated between January 2013 and December 2018 were classified into three groups: resectable (R), borderline resectable (BR), and unresectable (UR). We analyzed patient outcomes, including the rate of surgical resection and survival, in each of these groups. In total, 211 patients (R, 118; BR, 22; UR, 81) were selected. Among them, 117 (99%), 18 (82%), and 15 (19%) patients in the R, BR, and UR groups, respectively, underwent surgical resection. R0 resection rates were 88, 78, and 67%, whereas median overall survival (OS) from treatment initiation were 31, 18, and 11 months (p < 0.0001) in the R, BR, and UR groups, respectively. In patients who underwent surgical resection, relapse-free survival (RFS) and OS were similar among the three groups (R vs. BR vs. UR; median RFS (months), 17 vs. 13 vs. 11, p = 0.249; median OS (months), 31 vs. 26 vs. 32, p = 0.742). Lymph node metastases and incomplete adjuvant chemotherapy were identified as independent prognostic factors for OS. Although the surgical resection rate was low, particularly in the BR and UR groups, the prognosis of patients who underwent surgical resection was similar irrespective of the initial resectability status. MDPI 2023-02-09 /pmc/articles/PMC9954753/ /pubmed/36831444 http://dx.doi.org/10.3390/cancers15041101 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Einama, Takahiro
Takihata, Yasuhiro
Aosasa, Suefumi
Konno, Fukumi
Kobayashi, Kazuki
Yonamine, Naoto
Fujinuma, Ibuki
Tsunenari, Takazumi
Nakazawa, Akiko
Shinto, Eiji
Ueno, Hideki
Kishi, Yoji
Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience
title Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience
title_full Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience
title_fullStr Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience
title_full_unstemmed Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience
title_short Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience
title_sort prognosis of pancreatic cancer based on resectability: a single center experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954753/
https://www.ncbi.nlm.nih.gov/pubmed/36831444
http://dx.doi.org/10.3390/cancers15041101
work_keys_str_mv AT einamatakahiro prognosisofpancreaticcancerbasedonresectabilityasinglecenterexperience
AT takihatayasuhiro prognosisofpancreaticcancerbasedonresectabilityasinglecenterexperience
AT aosasasuefumi prognosisofpancreaticcancerbasedonresectabilityasinglecenterexperience
AT konnofukumi prognosisofpancreaticcancerbasedonresectabilityasinglecenterexperience
AT kobayashikazuki prognosisofpancreaticcancerbasedonresectabilityasinglecenterexperience
AT yonaminenaoto prognosisofpancreaticcancerbasedonresectabilityasinglecenterexperience
AT fujinumaibuki prognosisofpancreaticcancerbasedonresectabilityasinglecenterexperience
AT tsunenaritakazumi prognosisofpancreaticcancerbasedonresectabilityasinglecenterexperience
AT nakazawaakiko prognosisofpancreaticcancerbasedonresectabilityasinglecenterexperience
AT shintoeiji prognosisofpancreaticcancerbasedonresectabilityasinglecenterexperience
AT uenohideki prognosisofpancreaticcancerbasedonresectabilityasinglecenterexperience
AT kishiyoji prognosisofpancreaticcancerbasedonresectabilityasinglecenterexperience